Natalizumab in the treatment of Crohn’s disease
Danila Guagnozzi, Renzo CaprilliGastroenterology Unit, Department of Clinical Sciences, University of Rome “La Sapienza”, Rome, ItalyAbstract: The pathogenesis of Crohn’s disease (CD) is multifactorial and the activation of specific pathways of immunological...
Guardado en:
Autores principales: | Danila Guagnozzi, Renzo Caprilli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/53acc0a5dee3463594f9905aac2d678d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adalimumab for the treatment of Crohn’s disease
por: Andrea Cassinotti, et al.
Publicado: (2008) -
Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Renato Caviglia, et al.
Publicado: (2009) -
Natalizumab for the treatment of relapsing multiple sclerosis
por: Richard A Rudick, et al.
Publicado: (2008) -
Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Beate Hauptrock, et al.
Publicado: (2008) -
Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto S, et al.
Publicado: (2018)